tabrecta
novartis europharm limited - capmatinib dihydrochloride monohydrate - carcinom, ikke-småcellet lunge - antineoplastiske midler - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.
focetria
novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/california/7/2009 (h1n1)-derived strain used nymc x-181 - influenza, human; immunization; disease outbreaks - influenzavacciner - profylakse af influenza forårsaget af a (h1n1v) 2009 virus. focetria bør anvendes i overensstemmelse med officielle retningslinjer.
betoptic 5 mg/ml øjendråber, opløsning
novartis healthcare a/s - betaxololhydrochlorid - øjendråber, opløsning - 5 mg/ml
certican 0,25 mg dispergible tabletter
novartis healthcare a/s - everolimus - dispergible tabletter - 0,25 mg
certican 0,5 mg tabletter
novartis healthcare a/s - everolimus - tabletter - 0,5 mg
certican 0,75 mg tabletter
novartis healthcare a/s - everolimus - tabletter - 0,75 mg
ciflox 10+2 mg/ml øredråber, suspension
novartis healthcare a/s - ciprofloxacinhydrochlorid, vandfrit, hydrocortison - øredråber, suspension - 10+2 mg/ml
ciloxan 3 mg/ml øjendråber, opløsning
novartis healthcare a/s - ciprofloxacinhydrochlorid, vandfrit - øjendråber, opløsning - 3 mg/ml
ciloxan 3 mg/g øjensalve
novartis healthcare a/s - ciprofloxacinhydrochlorid, vandfrit - øjensalve - 3 mg/g
ciloxan 3 mg/ml øredråber, opløsning
novartis healthcare a/s - ciprofloxacinhydrochlorid, vandfrit - øredråber, opløsning - 3 mg/ml